Johnson & Johnson (JNJ)
NYSE · Healthcare · Drug Manufacturers - General
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
JNJ key fundamentals
- Price
- USD 270.61
- Market cap
- $652.14B
- P/E ratio
- 31.4
- P/S ratio
- 6.7
- EPS
- —
- Revenue (TTM)
- $94.19B
- Net margin
- 21.5%
- Return on equity
- 25.7%
- Debt / equity
- 0.58
- Dividend yield
- 1.95%
- 52-week high
- 281.07
- 52-week low
- 173.33
Statement figures as of 2025-12-28. Market data may be delayed.
How does JNJ measure against your lens?
FIS measures Johnson & Johnson against nine fundamental criteria — but which ones matter depends on how you invest. Your lens — growth, value, income, conservative, or balanced — is derived from your preferences, and the same company aligns differently through each. Sign up to see which criteria JNJ meets through your lens, in plain English.
- P/E Ratio
- P/S Ratio
- Net Profit Margin
- Return on Equity
- Revenue Growth (YoY)
- EPS Growth (YoY)
- Debt / Equity
- Current Ratio
- Dividend Yield
Free 30-day Pro trial. No credit card required.
This page describes Johnson & Johnson's reported financials and the criteria FIS measures. It is not a rating of the company and not a recommendation to buy, hold, or sell any security.